52 results about "Synthetic cannabinoids" patented technology

The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients.

The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.

The present invention relates to a synthetic cannabinoid, dexanabinol, of enantiomeric purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compositions comprising said compound of high enantiomeric purity, and uses thereof for prevention and treatment of neurological disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.

The present invention relates to pharmaceutical compositions comprising cannabinoids or mimics thereof. In one aspect, the invention provides transdermal formulations comprising cannabinoids or mimics thereof. In another aspect, the invention provides topical formulations comprising cannabinoids or mimics thereof. In one embodiment the formulations and compositions of the invention comprise nano colloidal silica. The formulations of the invention can be used in the therapeutic treatment of many conditions, including wherein the cannabinoids or mimics thereof are known to reduce the excessive neuronal firing characteristic of neuropathic pain. Muscle spasticity is also benefited by these formulations.

The present invention discloses a composition comprising cannabis natural extract, or synthetic cannabinoids, for use in treating a subject suffering from fibromyalgia. The present invention further discloses methods and uses of the aforementioned composition.

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits.

Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.

Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The cannabinoids suitable for use include cannabidiols, cannabinols, and various other naturally occurring and synthetic cannabinoids. The compositions may also further include anti-inflammatory agents, steroids, or terpenoids. In preferred embodiments, the cannabinoids incorporated in the compositions are cannabidiol (CBD) and cannabinol (CBN) while the carriers are selected from the group consisting of Labrasol™, Transcutol™, lecithin, lysolecithin, isopropyl palmitate, and isopropyl myristate.

The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients.

Synthetic cannabinoid medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The synthetic cannabinoid composition/carrier combinations can create administration benefits.

Rapid onset and extended action plant-based medicinal compounds or nutritional supplements and synthetic cannabinoid formulations are described. Rapid onset is provided by N-acylated fatty amino acids and/or penetration enhancers. Extended action can be provided by one or more sustained-release systems.

The subject invention provides materials and methods for single-step detection of small molecules, e.g., natural and synthetic cannabinoids, in a sample. The subjection invention provides nucleic acids materials, e.g., aptamers (nucleic acid oligonucleotides) that can bind to natural and/or synthetic cannabinoids. The method for detecting a natural or synthetic cannabinoid in a sample comprises contacting the sample with an aptamer-based sensor selective for the natural or synthetic cannabinoid, and sensitively and rapidly detecting the natural or synthetic cannabinoid in the sample. The aptamer-based sensor comprises aptamers that can specifically binds to natural and/or synthetic cannabinoids with nanomolar dissociation constant.

The invention discloses a detection method of indazole derivatives. The detection method comprises a qualitative detection method of gas chromatography-mass spectrometry, a qualitative detection method of gas chromatography and a quantitative detection method of gas chromatography, and is suitable for qualitative and quantitative detection and identification of indazole derivatives in solid test materials for drug cases. According to the invention, a qualitative and quantitative analysis method for the indazolamide synthetic cannabinoid is established by utilizing the commonly used gas chromatography and gas chromatography-mass spectrometry technology, and the method is quick, simple, convenient and easy to operate, is convenient to popularize and apply, can meet the requirements of judicial identification departments on the handling of such cases, and provides a basis for the smooth litigation of such cases.

The present invention provides a method for detecting synthetic indole and indazole cannabinoids in a sample known or suspected to contain a synthetic indole or indazole cannabinoid. A deuterated solvent is added to the solid sample, creating a suspension. The suspension is mixed to release the cannabinoid from the solid sample. The suspension is subject to a NMR spectroscopy process to produce a sample NMR spectrum. The synthetic cannabinoid is detected in the suspension by analysis of the sample NMR spectrum. When one-dimensional proton NMR is used, detection of a first peak between 8.00 and 8.50 ppm and a second peak between 4.00 and 4.40 ppm, indicates the presence of a synthetic indole or indazole cannabinoid. When two-dimensional Correlation Spectroscopy (COSY) NMR is used, detection of a first spot between 6.50 and 9.00 ppm and a second spot between 1.50 and 4.50 ppm indicates the presence of a synthetic indole or indazole cannabinoid. The method is performed in the absence of chromatography and optionally, may be used to quantify the amount of synthetic cannabinoid.

The invention discloses a magnetic nano-material for detecting tetrahydrocannabinoid and synthetic cannabinoid drugs. The magnetic nano-material is Fe3O4 (at) PDA (at) poly (MAA-co-EGDMA). Wherein the Fe3O4 is located at the core, the outer layer of the Fe3O4 is wrapped with the polydopamine to form a core-shell layer, and the core-shell layer is wrapped with the polymethylacrylic acid crosslinked ethylene glycol dimethacrylate to serve as a loading layer. The prepared Fe3O4 (at) PDA (at) poly (MAA-co-EGDMA) magnetic nano material has the advantages that the complex matrix sample treatment process is simplified, the sensitivity of an instrument for detecting tetrahydrocannabinoic acid and synthetic cannabinoid drugs is greatly improved, the magnetic nano material can be matched with an on-site rapid detection instrument or a laboratory large-scale analysis instrument for use, pretreatment steps are reduced, the cost is reduced, and the detection efficiency is improved. The characteristics of complicated steps and low repeatability in the prior art are avoided, and high-flux automatic detection of trace drugs in sewage and urine is realized.

The invention discloses an in-vivo biomarker for detecting 5F-AMB and application thereof. The in-vivo biomarker of synthetic cannabinoid 5F-AMB is detected as shown in Table 1. The in-vivo biomarkerfor detecting 5F-AMB and the application thereof overcome the defects of high in-vivo metabolism speed of the synthetic cannabinoid 5F-AMB and generally lower parent drug content in a biological detection material, and the invention provides a method for detecting by using an in-vivo metabolism marker, which has the advantages of high accuracy, high sensitivity and an accurate and reliable result.The biomass of the detection sample required by the invention is less and is only 100 microliters.

The invention discloses a cannabinoid active substance detection method based on an intracellular free Ca<2+> concentration change effect and a cannabinoid active substance detection kit. The detection kit comprises two components including a detection group reagent and a negative control group reagent, the detection group reagent comprises a monoclonal cell line CB1/293 stably expressing a human-derived cannabinoid receptor CB1 gene and an intracellular free Ca<2+> probe reagent Fluo 3-AM; the negative control group reagent comprises the monoclonal cell line CB1/293 stably expressing the human-derived cannabinoid receptor CB1 gene, the intracellular free Ca<2+> probe reagent Fluo 3-AM and a cannabinoid receptor antagonist. With the adoption of the detection method, accurate, high-sensitivity and rapid detection of all cannabinoid active substances including natural cannabinoid and synthetic cannabinoid as well as novel synthetic cannabinoid active substances which emerge in endlesslycan be realized, and the problem of difficulty in supervising cannabis psychoactive substances can be solved.

A composition comprising a cannabinoid, in particular a phytocannabinoid or a synthetic cannabinoid, wherein the cannabinoid is stabilised against oxidation and/or photochemical degradation, characterized in that the composition comprises a micellar solution of poloxamer-based micelles in an aqueous solution and where the poloxamer micelles encapsulate the cannabinoid.